tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Larimar Therapeutics Advances Nomlabofusp Program Amid Financial Losses
PremiumCompany AnnouncementsLarimar Therapeutics Advances Nomlabofusp Program Amid Financial Losses
14d ago
Promising Data and Optimistic Outlook Drive Buy Rating for Larimar Therapeutics
Premium
Ratings
Promising Data and Optimistic Outlook Drive Buy Rating for Larimar Therapeutics
14d ago
Larimar Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Larimar Therapeutics Reports Q2 2025 Financial Results
14d ago
Larimar Therapeutics announces common stock offering, no amount given
PremiumThe FlyLarimar Therapeutics announces common stock offering, no amount given
30d ago
Promising Potential of Larimar Therapeutics’ Nomlabofusp in Friedreich’s Ataxia: A Buy Rating Justified
Premium
Ratings
Promising Potential of Larimar Therapeutics’ Nomlabofusp in Friedreich’s Ataxia: A Buy Rating Justified
2M ago
Positive Outlook for Larimar Therapeutics: Promising Data on Nomlabofusp and Anticipated Catalysts Drive Buy Rating
Premium
Ratings
Positive Outlook for Larimar Therapeutics: Promising Data on Nomlabofusp and Anticipated Catalysts Drive Buy Rating
2M ago
Larimar Therapeutics Updates on Nomlabofusp Progress
PremiumCompany AnnouncementsLarimar Therapeutics Updates on Nomlabofusp Progress
2M ago
Larimar Therapeutics: FDA Guidance Boosts Buy Rating Amid Promising Regulatory Progress
Premium
Ratings
Larimar Therapeutics: FDA Guidance Boosts Buy Rating Amid Promising Regulatory Progress
2M ago
Larimar Therapeutics Receives FDA Guidance for BLA Submission
Premium
Company Announcements
Larimar Therapeutics Receives FDA Guidance for BLA Submission
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100